Atopic Dermatitis

Self-reported anaphylaxis in adults appeared positively associated with the number of allergic diseases they had, according to a study published in Clinical and Translational Allergy.

Dupilumab had good overall survival for up to 3 years in patients with atopic dermatitis, according to a study.

“It’s a very exciting time in inflammatory skin diseases,” Emma Guttman-Yassky, MD, PhD, told Healio.

Patients with persistently controlled atopic dermatitis continued to experience stable and low disease activity after receiving reduced dosages of dupilumab, according to a study published in Allergy.

By inhibiting IL-4 and IL-13 signaling, dupilumab enabled the restoration of lipid composition and barrier function in the skin of patients with moderate to severe atopic dermatitis, according to a study published in Allergy.

Arcutis Biotherapeutics has completed patient enrollment for its phase 3 trial of roflumilast cream for the treatment of atopic dermatitis, the company announced in a press release.

Photoaggravated atopic dermatitis, which affects people of varied ages and with different skin phototypes, has a significant impact on quality of life, according to a study.

inimally invasive tape strips capture immune-related and barrier-related markers of atopic dermatitis in lesional and non-lesional skin across pediatric age groups, according to a letter published in Allergy.

Tralokinumab led to early and clinically meaningful improvements in patient-reported outcomes for moderate to severe atopic dermatitis compared with placebo, according to a study published in Annals of Allergy, Asthma & Immunology.

Asthma or atopic dermatitis among parents may predict atopic dermatitis risk in their offspring, according to recent findings.